Efbemalenograstim alfa for prophylaxis in non–small cell lung cancer patients patients with chemotherapy-induced febrile neutropenia: A randomized, multicenter, exploratory clinical trial.

8657 Background: Neutropenia is a common dose-limiting chemotherapy toxicity, with its severity and duration impairing therapeutic efficacy. In NSCLC management, chemotherapy regimens with high risk febrile neutropenia (FN) are relatively uncommon. However, real-world data show suboptimal prophylactic granulocyte colony-stimulating factor (G-CSF) use in intermediate risk FN patients with additional risk factors. This study evaluated efbemalenograstim alfa's efficacy and safety in maintaining abs